MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.88
-0.50
-5.33%
After Hours: 8.60 -0.28 -3.15% 17:58 02/25 EST
OPEN
9.40
PREV CLOSE
9.38
HIGH
9.49
LOW
8.75
VOLUME
908.99K
TURNOVER
--
52 WEEK HIGH
15.65
52 WEEK LOW
4.260
MARKET CAP
547.21M
P/E (TTM)
-5.3695
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter...
BusinessWire · 12h ago
8-K: Syros Pharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- false 0001556263 0001556263 2021-02-25 2021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 13h ago
Syros to Participate in Upcoming Investor Conferences in March
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that members of its management team will participate in panel discussions and present a corporate overview at upcoming inves...
Business Wire · 3d ago
Cyclin Dependent Kinase 7 Market Size, Growth and Forecast 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 02:34:13 / Comserve Inc. / -- Cyclin Dependent Kinase 7 market is segmented by Type, and by Application. Players, stakeholders,...
Comserve · 3d ago
Cyclin Dependent Kinase 7 Market Size 2021 Share Estimation, On Going Trends, Top Players Updates, Consumer-Demand, Developments Plans, Industry Impact and Forecast till 2027, Says Industry Research Biz
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Cyclin Dependent Kinase 7...
The Express Wire · 02/18 05:07
Cancer CDK Inhibitors Market to Eyewitness Massive Growth by 2026 | Pfizer, Bayer, Piramal, BioCAD
Feb 11, 2021 (Market Insight Reports) -- Stay up-to-date and exploit latest trends of Cancer CDK Inhibitors Market with latest edition released by AMA....
Market Insight Reports · 02/11 15:09
Cyclin Dependent Kinase 7 Market Size Analysis By Current Industry Status & Growth Opportunities, Top Key Players, Target Audience And Forecast To 2026
Feb 09, 2021 (The Expresswire) -- “Global Cyclin Dependent Kinase 7 Market" Report2021-2026contains systematic and point to point information regarding to...
The Express Wire · 02/09 10:36
InvestorNewsbreaks - Syros Pharmaceuticals (NASDAQ: SYRS) Closes Underwritten Public Offering of $75.6 Million
Jan 27, 2021 (Investor Brand Network via COMTEX) -- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the...
Investor Brand Network · 01/27 14:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYRS. Analyze the recent business situations of Syros Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYRS stock price target is 17.14 with a high estimate of 20.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 146
Institutional Holdings: 58.69M
% Owned: 95.25%
Shares Outstanding: 61.62M
TypeInstitutionsShares
Increased
36
2.28M
New
40
12.01M
Decreased
29
3.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.83%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Nancy Simonian
Chief Financial Officer
Joseph Ferra
Chief Scientific Officer
Eric Olson
Chief Accounting Officer
Colleen DeSimone
Other
Gerald Quirk
Other
David Roth
Other
Jeremy Springhorn
Director
S. Gail Eckhardt
Director
Richard Young
Independent Director
Srinivas Akkaraju
Independent Director
Mark Alles
Independent Director
Marsha Fanucci
Independent Director
Amir Nashat
Independent Director
Phillip Sharp
  • Dividends
  • Splits
  • Insider Activity
No Data
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.